Monday, June 23, 2025
  • Login
Euro Times
No Result
View All Result
  • Home
  • Finance
  • Business
  • World
  • Politics
  • Markets
  • Stock Market
  • Cryptocurrency
  • Investing
  • Health
  • Technology
  • Home
  • Finance
  • Business
  • World
  • Politics
  • Markets
  • Stock Market
  • Cryptocurrency
  • Investing
  • Health
  • Technology
Euro Times
No Result
View All Result

An experimental Alzheimer’s drug could be approved next year. But it comes with risks : NPR

by Jon Hamilton
December 7, 2022
in Health
Reading Time: 3 mins read
A A
0
Home Health
Share on FacebookShare on Twitter


Researchers say the experimental Alzheimer’s drug Lecanemab represents an important advance and is likely to get FDA approval in 2023, despite some safety concerns.



STEVE INSKEEP, HOST:

An experimental drug is raising hope for the treatment of Alzheimer’s disease, although it does come with some risks. So NPR’s Jon Hamilton looked at the evidence.

JON HAMILTON, BYLINE: The drug, called lecanemab, only slows down Alzheimer’s a bit. But it dominated last week’s Clinical Trials on Alzheimer’s Disease meeting in San Francisco. Dr. Eric Reiman was there. He’s the executive director of Banner Alzheimer’s Institute in Phoenix.

ERIC REIMAN: There was a feeling of elation that this was a milestone in the fight against Alzheimer’s disease and very important.

HAMILTON: A study of nearly 1,800 people in the early stages of Alzheimer’s found that lecanemab slowed down declines in memory and thinking by 27%. Reiman says that’s a modest but meaningful benefit from the drug.

REIMAN: It had effects on a range of cognitive and functional measurements that are important to families and family caregivers. But clearly, a treatment by itself that is not going to stop the progression of the disease.

HAMILTON: Lecanemab contains antibodies designed to remove a substance called amyloid from the brain. That makes it similar to the controversial drug Aduhelm, which received a conditional approval from the Food and Drug Administration last year. The agency acted despite conflicting evidence on whether Aduhelm slows down the disease. Reiman says the results with lecanemab are much clearer.

REIMAN: I’ll be surprised if it doesn’t get full approval.

HAMILTON: Probably sometime next year. Both Aduhelm and lecanemab have risks, including a condition known as ARIA. Dr. Sharon Cohen, medical director of the Toronto Memory Program in Canada, says when a brain scan shows ARIA, it’s a sign of either swelling or bleeding.

SHARON COHEN: This sounds very dramatic to have swelling in the brain or bleeding in the brain, and of course, nobody wants that.

HAMILTON: But Cohen says even though ARIA is common, it rarely has a big impact on patients’ health.

COHEN: What we’ve learned over time is that a very small proportion of individuals will have symptoms, and when symptoms arise, they are usually transient, mild to moderate and resolve.

HAMILTON: In rare cases, though, patients can experience brain damage or even death. Cohen says the risks of ARIA appear to be higher in people who have very high levels of amyloid in the brain or are taking blood thinners.

COHEN: There will be patients for whom this is not a good therapy.

HAMILTON: Lecanemab and other drugs that remove amyloid have another side effect that is more mysterious. They seem to cause the brain to shrink. And that concerns Dr. Madhav Thambisetty, a neurologist at the National Institute on Aging, a part of the National Institutes of Health.

MADHAV THAMBISETTY: What is a little worrying to me is that these drugs might be worsening the degenerative process that is associated with disease progression.

HAMILTON: Alzheimer’s itself causes the brain to shrink, a sign that neurons are dying. So Thambisetty, whose views are independent of the NIH, expected Alzheimer’s drugs to limit shrinkage rather than accelerate it.

THAMBISETTY: It’s incumbent upon drug developers and researchers to try and prove that these changes are benign and do not represent a significant adverse event.

HAMILTON: Dr. Reisa Sperling directs the Center for Alzheimer’s Research and Treatment at Brigham and Women’s Hospital in Boston. She says serious side effects are common in treating other diseases like cancer.

REISA SPERLING: Alzheimer’s is a terrible disease, and I think many patients and their physicians will be willing to take some risk. And our work is to minimize the risk.

HAMILTON: About 2 million Alzheimer’s patients in the U.S. are potential candidates for lecanemab.

Jon Hamilton, NPR News.

Copyright © 2022 NPR. All rights reserved. Visit our website terms of use and permissions pages at www.npr.org for further information.

NPR transcripts are created on a rush deadline by an NPR contractor. This text may not be in its final form and may be updated or revised in the future. Accuracy and availability may vary. The authoritative record of NPR’s programming is the audio record.



Source link

Tags: AlzheimersApproveddrugExperimentalNPRRisksyear
Previous Post

Renewables to be main source of electricity generation by 2025: IEA

Next Post

Putin Signs Law Banning Expressions of L.G.B.T.Q. Identity in Russia : worldnews

Related Posts

Trump’s Medicaid cuts would have vast ripple effects in this rural Colorado valley : Shots

Trump’s Medicaid cuts would have vast ripple effects in this rural Colorado valley : Shots

by John Daley
June 22, 2025
0

The Sangre de Cristo mountains loom over Colorado's San Luis Valley. Many on this agricultural area voted for President Trump...

Having a Disrupted Body Clock Increases Your Risk of Early Death

Having a Disrupted Body Clock Increases Your Risk of Early Death

by Dr. Mercola
June 21, 2025
0

Mercola proudly helps these charities and organizations. View All Charities & Organizations Extra About Mercola.com Disclaimer: All the contents of...

Chicken Alfredo, Cereal, and Chocolate Almonds Pulled Over Health Risks

Chicken Alfredo, Cereal, and Chocolate Almonds Pulled Over Health Risks

by Jenna Anderson
June 21, 2025
0

The week of June 16 noticed three main recollects, together with one linked to a lethal Listeria outbreak. Examine your...

Dip Into Summer: The Healthiest Spreads for Every Party Table

Dip Into Summer: The Healthiest Spreads for Every Party Table

by Kelsey Costa, MS, RDN
June 21, 2025
0

With summer time snacks trending throughout social media, it’s time to degree up your occasion unfold with more healthy dip...

What children in poverty could lose from the ‘Big Beautiful Bill’ : NPR

What children in poverty could lose from the ‘Big Beautiful Bill’ : NPR

by Cory Turner
June 20, 2025
0

Republicans are proposing modifications that would end in some youngsters and households shedding entry to well being care, meals advantages...

What Actually Worked For Me

What Actually Worked For Me

by Katie Wells
June 22, 2025
0

Cortisol, also known as the “stress hormone,” is among the strongest hormones within the physique. Whereas cortisol’s main perform is...

Next Post
Putin Signs Law Banning Expressions of L.G.B.T.Q. Identity in Russia : worldnews

Putin Signs Law Banning Expressions of L.G.B.T.Q. Identity in Russia : worldnews

Alienware teases the return of its 18-inch gaming laptop

Alienware teases the return of its 18-inch gaming laptop

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Ares Alternative Credit To Buy 20% Stake In Eni Plenitude

Ares Alternative Credit To Buy 20% Stake In Eni Plenitude

June 23, 2025
First Trade: Nifty slips 150 points to trade at 24,961; IT gauge top loser

First Trade: Nifty slips 150 points to trade at 24,961; IT gauge top loser

June 23, 2025
The Best Space Stock Out There Is…

The Best Space Stock Out There Is…

June 23, 2025
Air India crash risks fueling up to 30% jump in insurance premiums

Air India crash risks fueling up to 30% jump in insurance premiums

June 23, 2025
One in seven people ‘have lost money to fraud in past year’

One in seven people ‘have lost money to fraud in past year’

June 23, 2025
Legacy News Omits Mahmoud Khalil’s Return Protest

Legacy News Omits Mahmoud Khalil’s Return Protest

June 23, 2025
Euro Times

Get the latest news and follow the coverage of Business & Financial News, Stock Market Updates, Analysis, and more from the trusted sources.

CATEGORIES

  • Business
  • Cryptocurrency
  • Finance
  • Health
  • Investing
  • Markets
  • Politics
  • Stock Market
  • Technology
  • Uncategorized
  • World

LATEST UPDATES

Ares Alternative Credit To Buy 20% Stake In Eni Plenitude

First Trade: Nifty slips 150 points to trade at 24,961; IT gauge top loser

  • Disclaimer
  • Privacy Policy
  • DMCA
  • Cookie Privacy Policy
  • Terms and Conditions
  • Contact us

Copyright © 2022 - Euro Times.
Euro Times is not responsible for the content of external sites.

No Result
View All Result
  • Home
  • Finance
  • Business
  • World
  • Politics
  • Markets
  • Stock Market
  • Cryptocurrency
  • Investing
  • Health
  • Technology

Copyright © 2022 - Euro Times.
Euro Times is not responsible for the content of external sites.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In